Health Care • Medical/Dental Instruments
$3.00 ▼ -0.31
(-9.37%)
MKT CAP: $32.4M • VOL: 55.5K
52W L $3 52W H $15
ROARABLE / RQD
E • 34/100
PIOTROSKI
5 / 9
DRIO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $22.4M | $27.0M | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $12.7M | $13.3M | — |
| Gross Margin % | 56.6% | 49.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$36.7M | -$57.7M | -$56.2M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$41.7M | -$42.7M | -$59.4M |
| EBITDA (Normalized) | -$36.5M | -$57.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$25.9M | -$38.6M | -$30.4M |
| Capital Expenditures (CapEx) | $142.0K | $138.0K | — |
| Free Cash Flow (FCF) | -$26.1M | -$38.7M | -$30.4M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -37.7% | -45.0% | — |
| Cash & Short-Term Equivalents | $21.8M | $27.8M | — |
| Total Debt (Short + Long Term) | $30.7M | $23.5M | — |
| Total Stockholders' Equity | $67.9M | $72.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DRIO.